NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Flaskworks I disagree. I think that is a moving target based on demand and how close they think they will be to commercialization.

An estimated quarter for TLD would be nice to have. I can see why they wouldn't do this as the ultimate publication is out of their hands. They might think they will be approved in Q2, but something comes up in the review and it is pushed back (or they have to apply to a different journal). What would be the benefit to publishing an estimated journal date? Satisfy some impatient posters on ihub. What is the downside? They miss the deadline (which is out of their control) and the negative blowback that comes with another missed deadline.

I disagree on both points Flipper. No point in offering timelines for an evolving and moving target.